The board should see the measure management was tempted to leave out.

I want an operating paper to explain the business the factory is being asked to support. The commercial offer can change faster than the production model, leaving management to absorb a different mix through repeated exceptions. A board should be able to examine that relationship without becoming responsible for the next machine schedule. My contribution as COO is to make the assumptions, trade-offs and authority boundaries visible enough for collective oversight to ask a useful question.

The small-order trial illustrates why the account needs more than its most attractive measure. Forty-two machine hours per week were reserved for ten weeks in a defined area. Local utilisation moved from 86% to 79%, while a selected on-time measure moved from seventy-three to eighty-eight orders across separate hundred-order cohorts. JPY 24 million additional expense was recorded. Those facts describe a trade-off, not an uncomplicated efficiency gain. Directors should understand the commercial purpose of serving that mix and the limits of the observation before considering any wider application.

I would also expect the original customer promise to remain visible. Changing a delivery date can be a legitimate commercial decision, but a performance account should not quietly substitute a revised promise when assessing the question the trial was intended to answer. The definition matters because an encouraging result can otherwise reflect a different commitment rather than a different operating capability. My role is to preserve the relevant account and explain its limitations, including the fact that separate order populations do not establish a controlled causal result.

Manufacturing investment needs an equally clear sequence of reasoning. In 2021 we authorised JPY 46 million for fixtures and tool-change work before committing to a proposed JPY 280 million cell. A median observation improved within one product family, based on twelve changeovers before and twelve afterward. The JPY 234 million difference was uncommitted capital, not a realised saving. A board-facing explanation should identify the question the smaller programme answered, the future requirement it did not settle and the condition that will bring the larger choice back for consideration.

The sponsor’s objection belongs in that explanation. Some intermediate work might be superseded if the larger cell were later approved. That possibility makes the cost of learning part of the decision. It should not be removed merely because the local result was encouraging. Directors can examine whether the stage was worthwhile while respecting the engineering, quality and safety decisions that remain with their authorised owners. An executive preference for a lower immediate commitment cannot replace those assessments.

The product-range review demonstrates a different boundary. Nine variants remained standard, twelve moved to made-to-order terms and six left new quotations. That classification changed the future offer; it did not cancel existing customer responsibilities. The JPY 37 million transition expense and the work of examining ongoing obligations remained in the account. A board should understand what management has chosen to offer, how customers will hear the change and whether the factory’s provision matches those terms. A catalogue decision is incomplete if separate parts of the business continue to communicate different promises.

My own supplier-consolidation mistake provides another useful question for oversight. Reducing twelve relationships to six simplified a purchasing account before we had adequately established how two specialist finishing requirements would be served. Restoring two qualified relationships brought the group to eight and required JPY 9 million additional expense. I would not want the original simplification reported as a continuing success with that correction omitted. The board should be able to see how management revisits an assumption it previously supported and whether the receiving operation’s evidence reaches the decision early enough.

Capability claims deserve similar discipline. A training programme does not establish authorisation simply because the participants attended. In the setup example, five of eight learners met the assessed requirements and three continued development, alongside four previously authorised colleagues. Reporting nine authorised people gave supervisors a more useful account than describing a twelve-person group as fully ready. The board does not assess each operator. It can ask whether the institution’s capacity claims depend on capability that has actually been established by the appropriate owners.

If appointed as a non-executive, I would bring this operating experience through the chair and the agreed committee structure. I have presented to the board as an executive and have no statutory director appointments. I would not use plant familiarity to create an informal instruction channel to managers. The contribution would be to test the connection between the commercial proposition, the operating evidence and the choices still unresolved. Learning the institution’s context would come before assuming that a familiar factory pattern had the same meaning there.

Conflicts, confidentiality and time would shape that contribution. Shared customers, suppliers or investors could make knowledge from my current role relevant in ways that require disclosure and proper assessment. Twenty-four days is a conditional capacity discussion after employer clearance, not an unconditional commitment to any board calendar. The proposition is therefore specific and limited: practical manufacturing judgement that may improve collective examination of an institution’s assumptions, offered without claiming independence, eligibility or appointment suitability has already been established.